Key result
Elevated admission C-reactive protein levels independently predicted 30-day major adverse cardiovascular events in acute myocardial infarction patients (adjusted OR 1.18 per 1 mg/L increase).
Why the study?
CRP has been proposed as a predictor of poor cardiovascular outcomes, but its role at admission needed evaluation for predicting short-term events in AMI.
Do elevated admission CRP levels predict 30-day major adverse cardiovascular events in patients with acute myocardial infarction?
Cohort (n=200)
No
Do elevated admission CRP levels predict 30-day major adverse cardiovascular events in patients with acute myocardial infarction?
Odds Ratio: 1.18 (95% CI 1.09–1.27)
Absolute Event Rate: 42.2% vs 8.6%
p-value: p=<0.001
Elevated admission CRP levels independently predict a higher risk of 30-day major adverse cardiovascular events in patients with acute myocardial infarction, supporting its utility for early risk stratification.
May aid early risk stratification in AMI; observational data leave open whether it guides therapy or improves outcomes.
Introduction Acute myocardial infarction (AMI) is a major cause of illness and mortality around the world. Anti-inflammatory biomarkers, especially C-reactive protein (CRP), which indicate the degree of cardiac injury and systemic inflammation, have been proposed as predictors of poor cardiovascular outcomes. Objective The main objective of this study is to evaluate the role of CRP levels at admission as a predictor of 30-day major adverse cardiovascular events (MACE) in patients with AMI. Methodology This prospective observational cohort study was conducted at Lady Reading Hospital and Medical Teaching Institute, Peshawar, Pakistan, over a 12-month period. A total of 200 patients presenting with confirmed AMI were enrolled. Baseline demographics, clinical characteristics, and laboratory parameters, including serum CRP, were recorded. Patients were stratified into three CRP groups: <5 mg/L, 5-10 mg/L, and >10 mg/L. The selected thresholds were based on established clinical interpretations of inflammatory activity, where CRP levels <5 mg/L indicate minimal inflammation, 5-10 mg/L reflect moderate inflammation, and >10 mg/L represent marked systemic inflammation, typically associated with acute disease states. The primary outcome was 30-day MACE, including death, reinfarction, and heart failure. Statistical analyses included Chi-square tests, one-way analysis of variance (ANOVA), and multivariable logistic regression to adjust for potential confounders. Results The mean age was 57.8 ± 10.6 years, with 132 (66%) males. Elevated CRP levels (>10 mg/L) were significantly associated with a higher incidence of MACE (19, 42.2%) compared to the moderate (21, 24.7%) and low CRP groups (6, 8.6%) (p < 0.001). Multivariable logistic regression confirmed CRP as an independent predictor of 30-day MACE (adjusted OR: 1.18 per 1 mg/L increase, 95% CI: 1.09-1.27, p < 0.001), alongside age, troponin, and time to hospital admission. Conclusion Admission CRP levels are a strong independent predictor of short-term adverse outcomes in AMI patients, and can be used for early risk stratification and management decisions.
No takes yet. Share an insight, caveat, or question.
Ahtesham et al. (2025) conducted a cohort in Acute myocardial infarction (AMI) (n=200). Elevated C-reactive protein (CRP) levels at admission vs. Low CRP levels (<5 mg/L) was evaluated on 30-day major adverse cardiovascular events (MACE) (OR 1.18, 95% CI 1.09-1.27, p=<0.001). Elevated admission C-reactive protein levels independently predicted 30-day major adverse cardiovascular events in acute myocardial infarction patients (adjusted OR 1.18 per 1 mg/L increase).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: